OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

CFO exercised or converted 7,500 UTHR derivative securities | OQRO

Home
Insider trades
United Therapeutics
CFO exercised or converted 7,500 UTHR derivative securities

Insider trades

Insider trade

CFO exercised or converted 7,500 UTHR derivative securities

Traded May 18, 2026 · Filed May 20, 2026

UTHUnited TherapeuticsUTHR

7,500
Shares · @ $117.76

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: May 18, 2026
Reporting period: Not applicable
Filed with the SEC: May 20, 2026

CFOOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001636178-26-000019

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

May 20, 2026, 12:32 AM UTC

Added to OQRO

Oct 6, 2026, 9:34 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

UNITED THERAPEUTICS Corp

Issuer CIK

1082554

Ticker

UTHR

Reporting person

James Edgemond

Relationship

Officer

Officer title

CFO AND TREASURER

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

May 18, 2026

Transaction code

Shares / units

7,500

Price per share

$117.76

Acquired / disposed

Acquired (A)

Shares owned after

28,876

Ownership form

Direct

Amendment

Footnotes from the filing

This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.

Around the same time

Paul A MahonEVP & GENERAL COUNSEL

Filed 4mo ago

8,300Shares · @ $146.03

Traded Jun 18 · filed 1 day later

Derivative exercise or conversion — not an open-market buy.

More Official record

Paul A Mahon (EVP & GENERAL COUNSEL) sold ~$921K of United Therapeutics

Scheduled in advanceFiled 4mo ago

Paul A Mahon (EVP & GENERAL COUNSEL) sold ~$515K of United Therapeutics

Scheduled in advanceFiled 4mo ago